Adult Onset IgA Vasculitis

1. Comprehensive Introduction & Overview

Adult-onset IgA Vasculitis (IgAV), formerly known as Henoch-Schönlein Purpura (HSP), is a systemic small-vessel vasculitis characterized by the deposition of immunoglobulin A (IgA1)-dominant immune complexes in the walls of small vessels. While traditionally recognized as a pediatric condition, IgAV in adults presents with a distinct clinical profile, often characterized by greater disease severity, higher rates of renal involvement, and a more protracted clinical course.

As an expert clinical guide, this document serves to clarify the diagnostic complexities of this multisystemic disorder. IgAV is classified as a "hypersensitivity vasculitis" under the Chapel Hill Consensus Conference criteria. It represents a significant clinical challenge due to its potential for rapid progression to end-stage renal disease (ESRD) and the necessity for aggressive immunosuppressive therapy in adult cohorts.

2. Deep-Dive: Etiology and Pathophysiology

The pathophysiology of IgAV is rooted in the abnormal glycosylation of IgA1 molecules. Understanding the molecular mechanism is vital for clinical management.

The Mechanism of Action

1. Galactose-Deficient IgA1 (Gd-IgA1): The core of the disease lies in the production of IgA1 molecules that lack terminal galactose residues in their hinge region.
2. Autoantibody Formation: These Gd-IgA1 molecules are recognized as "neoantigens," triggering the production of IgG or IgA autoantibodies directed against the exposed N-acetylgalactosamine (GalNAc) residues.
3. Immune Complex Formation: The resulting Gd-IgA1-IgG immune complexes circulate in the bloodstream.
4. Vessel Wall Deposition: These complexes deposit in the mesangium of the renal glomeruli and the small vessels of the skin, gastrointestinal tract, and joints.
5. Complement Activation: The deposited complexes activate the alternative complement pathway, leading to the recruitment of neutrophils and the release of inflammatory cytokines, resulting in leukocytoclastic vasculitis.

Etiological Triggers

Unlike pediatric cases, which are frequently triggered by upper respiratory tract infections (e.g., Streptococcus pyogenes), adult-onset cases often show a broader array of triggers:
* Infectious agents: Helicobacter pylori, Hepatitis B/C, and Parvovirus B19.
* Drugs: Vancomycin, ACE inhibitors, and non-steroidal anti-inflammatory drugs (NSAIDs).
* Malignancy: IgAV can occasionally function as a paraneoplastic syndrome, particularly in occult hematologic or solid organ malignancies.

3. Clinical Indications and Presentation

Adult-onset IgAV is clinically distinct from the pediatric phenotype. While children present with a classic triad, adults often present with more profound systemic involvement.

The Classic Tetrad of IgAV

Clinical Staging and Grading

There is no universally accepted "staging" system for IgAV, but clinicians often utilize the Oxford Classification (originally for IgA Nephropathy) to grade renal severity:

1. Grade I: Mesangial hypercellularity (<50% of glomeruli).
2. Grade II: Mesangial hypercellularity (>50% of glomeruli).
3. Grade III: Endocapillary or extracapillary hypercellularity in <50% of glomeruli.
4. Grade IV: Endocapillary or extracapillary hypercellularity in >50% of glomeruli.
5. Grade V: Tubular atrophy/interstitial fibrosis.

4. Differential Diagnosis

Distinguishing IgAV from other vasculitides is critical for therapeutic selection.

• ANCA-Associated Vasculitis (AAV): Microscopic polyangiitis often presents with purpura and renal failure but is distinguished by the presence of ANCA antibodies and lack of IgA deposition on biopsy.
• Cryoglobulinemic Vasculitis: Presents with purpura and renal involvement but is characterized by low C4 levels and the presence of serum cryoglobulins.
• Systemic Lupus Erythematosus (SLE): Can present with purpura and glomerulonephritis; distinguished by ANA, anti-dsDNA, and hypocomplementemia.
• IgA Nephropathy (Berger’s Disease): IgAV is essentially a systemic form of IgA nephropathy. If the patient has renal symptoms without extra-renal signs (purpura, arthritis), it is classified as IgA Nephropathy rather than IgAV.

5. Diagnostic Testing Protocols

A comprehensive workup for suspected Adult-Onset IgAV includes:

Laboratory Investigations

• Urinalysis: Essential for identifying microscopic hematuria and proteinuria.
• Serum Creatinine/eGFR: Baseline renal function monitoring.
• 24-hour Proteinuria/Albumin-Creatinine Ratio: Quantifying renal damage.
• Immunological Panel: ANA, ANCA, C3/C4 levels, and Cryoglobulins to rule out mimics.
• IgA Levels: Serum IgA may be elevated, though this is non-specific.

Gold Standard Diagnostic Test

Skin Biopsy: Performed on a fresh lesion (less than 24-48 hours old). Direct Immunofluorescence (DIF) will show characteristic granular IgA deposition in the dermal capillaries.
Renal Biopsy: Indicated if there is significant proteinuria (>1g/day), hematuria, or declining renal function. It reveals mesangial IgA deposits on immunofluorescence and varying degrees of proliferation.

6. Risks, Side Effects, and Therapeutic Management

Treatment strategy is dictated by the severity of organ involvement.

Therapeutic Tiers

1. Mild/Cutaneous Only: Supportive care, rest, hydration, and NSAIDs (with caution regarding renal risk).
2. Moderate (Arthritis/Abdominal Pain): Short-course corticosteroids (e.g., Prednisone 0.5–1 mg/kg/day).
3. Severe (Renal involvement/GI hemorrhage):
   • Pulse Methylprednisolone.
   • Cyclophosphamide for severe glomerulonephritis.
   • Rituximab or Azathioprine for refractory cases.
   • Plasma Exchange (PLEX) in cases of rapidly progressive glomerulonephritis (RPGN).

Risks and Contraindications

• Steroid-related risks: Hyperglycemia, hypertension, osteoporosis, and psychiatric disturbances.
• Cyclophosphamide: Risk of cystitis, infertility, and secondary malignancies.
• NSAIDs: Generally contraindicated in patients with active renal involvement or pre-existing renal impairment due to the risk of exacerbating acute kidney injury (AKI).

7. Long-term Prognosis

The prognosis for adult-onset IgAV is significantly guarded compared to children. Up to 30% of adults may progress to chronic kidney disease (CKD). Factors associated with poor prognosis include:
* Initial nephrotic-range proteinuria.
* Elevated serum creatinine at presentation.
* Hypertension.
* Histological findings of crescents in >50% of glomeruli on biopsy.

Long-term follow-up requires monitoring of blood pressure, urinalysis, and renal function for at least 2–5 years post-diagnosis.

8. Frequently Asked Questions (FAQ)

1. Is Adult-Onset IgAV contagious?

No. IgAV is an autoimmune-mediated condition triggered by immune complexes; it is not infectious or transmissible.

2. Why is it more severe in adults than in children?

Adults tend to have a higher frequency of renal involvement and a higher likelihood of persistent, chronic kidney damage compared to the self-limiting nature often seen in pediatric cases.

3. Can I take ibuprofen for my joint pain?

Caution is advised. NSAIDs can be nephrotoxic. If you have renal involvement, NSAIDs are strictly contraindicated. Consult your rheumatologist.

4. Is this condition hereditary?

There is no strong evidence of direct genetic inheritance, though there may be a genetic predisposition to abnormal IgA glycosylation.

5. Will I need dialysis?

Only in severe cases where the disease leads to rapidly progressive glomerulonephritis or end-stage renal disease. Early aggressive treatment aims to prevent this.

6. Does diet affect IgAV?

There is no specific "IgAV diet," but maintaining a healthy, low-sodium diet is beneficial for blood pressure management, which is crucial for renal health.

7. How long does the rash last?

The skin purpura typically resolves in 2–4 weeks, but recurrent crops of lesions can occur over several months.

8. Is a biopsy always necessary?

A skin biopsy is standard for diagnosis. A renal biopsy is reserved for patients with signs of kidney involvement to guide treatment intensity.

9. Can IgAV return?

Yes, recurrence occurs in approximately 10–20% of adult patients, often triggered by subsequent infections.

10. What is the most important test to monitor?

The urinalysis is the most critical tool. Monitoring for hematuria and proteinuria allows for the early detection of silent renal progression.

Disclaimer: This guide is intended for educational purposes for healthcare professionals and clinical students. It does not replace individual clinical judgment or institutional guidelines. Always consult with a board-certified rheumatologist or nephrologist when managing complex systemic vasculitis cases.